TELA TELA Bio (TELA) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001561921
Activist 13DC-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
21
13F, latest reported quarter
What the filings say about TELA
Insiders, 180 days
+$186.0K net bought
2 buyers
Activist stakes (13D), 180 days
1 filing
Largest: 17.2% of the class
TELA Bio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, TELA Bio, Inc. insiders bought a net $186.0K of stock across 207 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Sep 16, 2026.
- The trade is 13.9% of the 179,827 shares held after it.
- No other insider bought within 30 days.
- 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Capper Joseph H bought about $30.5K of TELA on Sep 17, 2026; 21 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 15, 2026.
- The trade is 32.3% of the 154,827 shares held after it.
- 1 other insider bought within 30 days.
- 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Capper Joseph H bought about $58.3K of TELA on Sep 16, 2026; 1 other insider bought within 30 days and 21 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 14, 2026.
- The trade is 47.7% of the 104,827 shares held after it.
- 1 other insider bought within 30 days.
- 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Capper Joseph H bought about $52.9K of TELA on Sep 15, 2026; 1 other insider bought within 30 days and 21 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 45.6% of the 54,827 shares held after it.
- 1 other insider bought within 30 days.
- 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Capper Joseph H bought about $25.5K of TELA on Sep 14, 2026; 1 other insider bought within 30 days and 21 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 14, 2026.
- The trade is 2.3% of the 532,500 shares held after it.
- 1 other insider bought within 30 days.
- 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Getz Heather C bought about $8.3K of TELA on Aug 17, 2026; 1 other insider bought within 30 days and 21 funds added in the latest 13F quarter.207 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$186.0K over 180 days
+$186.0K over 90 days
more than 77% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
21 funds bought in last quarter
below 71% of Medical Devices
Revenue
+15.8% year over year
more than 63% of Medical Devices
Margin
-48.4% net margin
below 67% of Medical Devices
Buybacks
no share repurchases reported
Short interest
3.0% of the float short (float per yahoo 2026-10-27) · 3.8 days to cover · settled 2026-10-15
below 67% of Medical Devices
The situation: each line is one rule over one dataset
EW HEALTHCARE PARTNERS FUND 2, L.P. disclosed a 5%+ stake (6.77%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TELA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-35.6%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TELA: institutional holders (13F)
13F holdings, latest reported quarter
11,788,228 sh
$8.8M
7,714,709 sh
$5.8M
5,324,854 sh
$4.0M
2,137,201 sh
$1.6M
1,568,218 sh
$1.2M
Congress trades in TELA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
EW HEALTHCARE PARTNERS FUND 2, L.P.
Activist 13D · 2026-06-09
6.77%
EW HEALTHCARE PARTNERS FUND 2-A, L.P.
Activist 13D · 2026-06-09
10.46%
EW Healthcare Partners Fund 2-GP, L.P.
Activist 13D · 2026-06-09
17.23%
EW Healthcare Partners Fund 2-UGP, LLC
Activist 13D · 2026-06-09
17.23%
TELA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TELA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Jacob Discovery Fund
$77.4K position · as of 2026-05-31
0.5%
Fidelity Extended Market Index Fund
$210.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$292.1K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$18.1K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$53.7K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$64.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $186.0K bought by insiders over 180 days, 21 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TELA financials
Revenue growth
+15.8%
XBRL, annual
Net margin
-48.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$79.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TELA
| FY Dec 2025 | $80.3M |
| FY Dec 2024 | $69.3M |
| FY Dec 2023 | $58.5M |
| FY Dec 2022 | $41.4M |
| FY Dec 2021 | $29.5M |
| Jun 2026 | $19.3M |
| Mar 2026 | $19.1M |
| Dec 2025 | $20.9M |
| Sep 2025 | $20.7M |
| Jun 2025 | $20.2M |
| Mar 2025 | $18.5M |
| Dec 2024 | $17.6M |
| Sep 2024 | $19.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-51.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TELA
| FY Dec 2025 | -48.3% |
| FY Dec 2024 | -54.5% |
| FY Dec 2023 | -79.9% |
| FY Dec 2022 | -106.9% |
| FY Dec 2021 | -112.9% |
| Jun 2026 | -58.4% |
| Mar 2026 | -64.4% |
| Dec 2025 | -43.2% |
| Sep 2025 | -41.6% |
| Jun 2025 | -49.1% |
| Mar 2025 | -60.8% |
| Dec 2024 | -51.9% |
| Sep 2024 | -54.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$31.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TELA
| FY Dec 2025 | -$28.7M |
| FY Dec 2024 | -$42.6M |
| FY Dec 2023 | -$41.5M |
| FY Dec 2022 | -$41.6M |
| FY Dec 2021 | -$31.1M |
| Jun 2026 | -$9.4M |
| Mar 2026 | -$11.3M |
| Dec 2025 | -$5.0M |
| Sep 2025 | -$5.9M |
| Jun 2025 | -$8.0M |
| Mar 2025 | -$9.8M |
| Dec 2024 | -$7.8M |
| Sep 2024 | -$9.1M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity TELA
| FY Dec 2025 | 9.34x |
| FY Dec 2024 | 1.45x |
| FY Dec 2023 | 2.15x |
| FY Dec 2022 | 2.79x |
| FY Dec 2021 | 1.57x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 9.34x |
| Sep 2025 | 28.79x |
| Jun 2025 | 4.51x |
| Mar 2025 | 2.28x |
| Dec 2024 | 1.45x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.52x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-06-30 (12 months older than the period end)
Cash flow to debt TELA
| FY Dec 2025 | -0.48x |
| FY Dec 2024 | -1.01x |
| FY Dec 2023 | -1.01x |
| FY Dec 2022 | -1.02x |
| FY Dec 2021 | -0.97x |
| Jun 2026 | -0.52x |
| Mar 2026 | -0.50x |
| Dec 2025 | -0.48x |
| Sep 2025 | -0.69x |
| Jun 2025 | -0.83x |
| Mar 2025 | -0.89x |
| Dec 2024 | -1.01x |
| Sep 2024 | -1.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity TELA
| FY Dec 2025 | -223.2% |
| FY Dec 2024 | -159.7% |
| FY Dec 2023 | -281.4% |
| FY Dec 2022 | -257.5% |
| FY Dec 2021 | -96.3% |
| Jun 2026 | n/a |
| Mar 2026 | -616.1% |
| Dec 2025 | -223.2% |
| Sep 2025 | n/a |
| Jun 2025 | -675.7% |
| Mar 2025 | -267.0% |
| Dec 2024 | -159.7% |
| Sep 2024 | -342.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-64.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TELA
| FY Dec 2025 | -46.2% |
| FY Dec 2024 | -45.9% |
| FY Dec 2023 | -64.0% |
| FY Dec 2022 | -67.9% |
| FY Dec 2021 | -44.7% |
| Jun 2026 | -64.7% |
| Mar 2026 | -54.1% |
| Dec 2025 | -46.2% |
| Sep 2025 | -68.0% |
| Jun 2025 | -63.8% |
| Mar 2025 | -58.2% |
| Dec 2024 | -45.9% |
| Sep 2024 | -59.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital TELA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-75.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TELA
| FY Dec 2025 | -50.2% |
| FY Dec 2024 | -51.7% |
| FY Dec 2023 | -75.6% |
| FY Dec 2022 | -72.6% |
| FY Dec 2021 | -44.7% |
| Jun 2026 | -75.6% |
| Mar 2026 | -60.0% |
| Dec 2025 | -50.2% |
| Sep 2025 | -87.8% |
| Jun 2025 | -79.6% |
| Mar 2025 | -67.8% |
| Dec 2024 | -51.7% |
| Sep 2024 | -70.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TELA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$72.1M
market value at close 2026-10-27 on 2026-08-05 shares, plus long-term 2026-06-30 plus current 2025-06-30 (12 months older than the period end), minus cash 2026-06-30
Enterprise value TELA
| FY Dec 2025 | $55.7M |
| FY Dec 2024 | $107.4M |
| FY Dec 2023 | $155.9M |
| FY Dec 2022 | $218.2M |
| FY Dec 2021 | $173.2M |
| Jun 2026 | $62.6M |
| Mar 2026 | $47.4M |
| Dec 2025 | $55.7M |
| Sep 2025 | $74.1M |
| Jun 2025 | $83.1M |
| Mar 2025 | $46.7M |
| Dec 2024 | $107.4M |
| Sep 2024 | $86.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-73.4%
TTM free cash flow over market value at close 2026-10-27
FCF yield TELA
| FY Dec 2025 | -60.2% |
| FY Dec 2024 | -35.8% |
| FY Dec 2023 | -25.6% |
| FY Dec 2022 | -18.9% |
| FY Dec 2021 | -16.7% |
| Jun 2026 | -94.2% |
| Mar 2026 | -108.9% |
| Dec 2025 | -60.2% |
| Sep 2025 | -53.4% |
| Jun 2025 | -45.2% |
| Mar 2025 | -78.0% |
| Dec 2024 | -35.8% |
| Sep 2024 | -73.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TELA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M |
| Gross profit | $54.3M | $46.5M | $40.1M | $27.0M |
| Operating income | -$33.8M | -$34.1M | -$44.1M | -$39.0M |
| Net income | -$38.8M | -$37.8M | -$46.7M | -$44.3M |
| EPS (diluted) | -0.83 | -1.33 | -2.04 | -2.72 |
| Operating cash flow | -$28.2M | -$41.6M | -$40.9M | -$40.7M |
| Cash | $50.8M | $52.7M | $46.7M | $42.0M |
| Long-term debt | $55.7M | $41.1M | $40.5M | $39.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
TELA Stock Sonar score 6/7 axes
Find similar shapesCompareTELA ranks highest on insider conviction (75th percentile) and risk and compliance (73rd), and lowest on profitability (25th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TELA filings, in plain words
Are TELA Bio insiders buying or selling TELA?
In the 180 days to 2026-10-28, TELA Bio insiders were net buyers, a net $186.0K across purchases and sales reported on Form 4, by 2 buyers.
Read the full summary
In the 180 days to 2026-10-28, TELA Bio insiders were net buyers of TELA, a net $186.0K across purchases and sales reported on Form 4 by 2 buyers. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 17.2% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
